88 institutions hold shares in MediciNova Inc. (MNOV), with 3.55M shares held by insiders accounting for 7.30% while institutional investors hold 36.96% of the company’s shares. The shares outstanding are 44.97M, and float is at 40.37M with Short Float at 7.75%. Institutions hold 34.26% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 3.31 million shares valued at $17.43 million. The investor’s holdings represent 6.81% of the MNOV Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 1.96 million shares valued at $10.33 million to account for 4.04% of the shares outstanding. The other top investors are Essex Woodlands Management Inc. which holds 1.11 million shares representing 2.27% and valued at over $5.82 million, while State Street Corporation holds 1.53% of the shares totaling 0.74 million with a market value of $3.91 million.
MediciNova Inc. (NASDAQ: MNOV) is -8.17% lower on its value in year-to-date trading and has touched a low of $4.28 and a high of $13.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MNOV stock was last observed hovering at around $4.84 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $17.88 for the next 12 months. It is also 81.77% off the consensus price target high of $26.50 offered by 3 analysts, but current levels are 56.09% higher than the price target low of $11.00 for the same period.
Currently trading at $4.83, the stock is 2.32% and -9.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.37 million and changing -0.21% at the moment leaves the stock -14.92% off its SMA200. MNOV registered -10.56% loss for a year compared to 6-month loss of -12.18%. The firm has a 50-day simple moving average (SMA 50) of $5.2047 and a 200-day simple moving average (SMA200) of $5.6497.
The stock witnessed a 0.42% gain in the last 1 month and extending the period to 3 months gives it a -19.10%, and is 7.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.12% over the week and 4.79% over the month.
Distance from 52-week low is 12.85% and -63.55% from its 52-week high.
MediciNova Inc. (MNOV) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for MediciNova Inc. (MNOV) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
MediciNova Inc. is expected to release its quarterly report on 07/28/2021 and quarterly earnings per share for the current quarter are estimated at -$0.08.The EPS is expected to shrink by -4.00% this year.
MediciNova Inc. (MNOV) Insider Activity
A total of 2 insider transactions have happened at MediciNova Inc. (MNOV) in the last six months, with sales accounting for 1 and purchases happening 1 times. The most recent transaction is an insider sale by Nagao Hideki, the company’s Director. SEC filings show that Nagao Hideki sold 2,354 shares of the company’s common stock on Mar 11 at a price of $7.40 per share for a total of $17420.0. Following the sale, the insider now owns 12646.0 shares.
MediciNova Inc. disclosed in a document filed with the SEC on Sep 15 that Nagao Hideki (Director) sold a total of 1,000 shares of the company’s common stock. The trade occurred on Sep 15 and was made at $5.78 per share for $5780.0. Following the transaction, the insider now directly holds 15000.0 shares of the MNOV stock.
MediciNova Inc. (MNOV): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 14.78% up over the past 12 months. Novartis AG (NVS) is -1.39% down on the 1-year trading charts. Short interest in the company’s stock has risen 0.63% from the last report on Apr 14, 2021 to stand at a total of 3.13 million short shares sold with a short interest ratio of 4.9.